Breast Cancer
Vaccine Therapy for HER2+ Stage IV Breast Cancer
Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01729884
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Investigator: Jennifer M. Specht, MD; Conditions: Locally Recurrent Breast Cancer, Metastatic Breast Cancer; Status: Recruiting; Study ID: NCT01492101
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Investigator: Jennifer M. Specht, MD; Conditions: Breast Cancer; Status: Temporarily On Hold; Study ID: NCT01565083
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)
Investigator: Jennifer Specht, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00733408
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Investigator: Eve Rodler, MD; Conditions: Advanced Breast Cancer; Status: Recruiting; Study ID: NCT01104259
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
Investigator: George Laramore, MD; Conditions: Breast Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT00103181
A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Parenchymal and Leptomeningeal Metastases from Breast Cancer
Investigator: Maciej Mrugala, MD, PhD; Conditions: Stage IV Breast Cancer, Central Nervous System Involvement/Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Tumors Metastatic to Brain; Status: Open; Study ID: NCT00992602
Phase I-II Study of HER2 Vaccination with poly(I) poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01355393
Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab (Herceptin), Lapatinib (Tykerb), or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer
Investigator: ; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00770809
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B
Investigator: Hannah Linden, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01720602
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)
Investigator: Larissa Korde; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01042379
A Phase 2 Study of [18F]fluoroestradiol (FES) Imaging and Response to Hormonal Therapy
Investigator: David Mankoff, M.D., PhD ; Conditions: Breast Cancer; Status: Recruiting
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy
Investigator: David Mankoff, M.D., PhD ; Conditions: Breast Cancer; Status: Recruiting
A Phase III clinical trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent boost versus standard Whole Breast Irradiation plus sequential boost for early-stage breast cancer.
Investigator: George Laramore, MD; Conditions: Breast cancer; Status: Recruiting; Study ID: NCT01349322
Join Us On